Ampligen Approval Status
FDA Approved: No
Brand name: Ampligen
Generic name: rintatolimod
Company: Hemispherx Biopharma, Inc.
Treatment for: Chronic Fatigue Syndrome
Ampligen (rintatolimod) is an experimental nucleic acid therapeutic in development for the treatment of a variety of chronic diseases and viral disorders.
Development Status and FDA Approval Process for Ampligen
|Feb 9, 2015||Hemispherx Biopharma Posts USAMRIID Ebola Study Concluding Ampligen Produced 100% Survival Rate in Rodents with 100% Mortality in Placebo|
|Dec 9, 2014||Hemispherx Announces Data Showing Inhibition of Ebola by Ampligen Enlarged by Howard University Research|
|Feb 5, 2013||Hemispherx Biopharma Receives Complete Response Letter From FDA on Ampligen New Drug Application for Chronic Fatigue Syndrome|
|Dec 27, 2012||FDA Advisory Committee Makes Recommendations on Ampligen for Chronic Fatigue Syndrome|
|Oct 23, 2012||Hemispherx Biopharma Announces FDA Confirms Advisory Committee Meeting on December 20, 2012|
|Sep 24, 2012||Hemispherx Biopharma Announces FDA Advisory Committee Will Review Ampligen for Chronic Fatigue Syndrome|
|Aug 14, 2012||FDA Accepts Complete Response Submission Regarding the Ampligen New Drug Application for Chronic Fatigue Syndrome|
|Aug 1, 2012||Hemispherx Biopharma Files Complete Response With the FDA Regarding Its Ampligen New Drug Application for Chronic Fatigue Syndrome|
|Mar 7, 2008||Hemispherx Biopharma Reaches Agreement With FDA on Specific Steps
to Achieve Complete NDA on Proposed CFS Treatment Ampligen|
|Jan 9, 2008||Hemispherx Biopharma Addresses FDA Questions On Ampligen NDA|
|Oct 11, 2007||Hemispherx Biopharma Files New Drug Application for Ampligen as
Treatment for Chronic Fatigue Syndrome|
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.